We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
+10.92%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$43.9B
AUM Growth
+$2.87B
(+7%)
Cap. Flow
-$890M
Cap. Flow
% of AUM
-2.03%
Top 10 Holdings %
Top 10 Hldgs %
13.25%
Holding
2,343
New
170
Increased
997
Reduced
1,015
Closed
150
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$111M |
| 2 |
Verizon
VZ
|
+$103M |
| 3 |
AT&T
T
|
+$103M |
| 4 |
Kroger
KR
|
+$97.1M |
| 5 |
3M
MMM
|
+$92.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$138M |
| 2 |
Tesla
TSLA
|
+$110M |
| 3 |
JPMorgan Chase
JPM
|
+$103M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$89.4M |
| 5 |
Apple
AAPL
|
+$85.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 16.25% |
| 3 | Financials | 11.85% |
| 4 | Industrials | 11.44% |
| 5 | Consumer Discretionary | 10.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1701
FormFactor
FORM
$9.46B
| $681K | ﹤0.01% |
30,639
-12,359
| -29% | -$288K |
|
1702
Sturm, Ruger & Co
RGR
$598M
| $679K | ﹤0.01% |
13,420
+2,289
| +21% | +$124K |
|
1703
Forward Air
FWRD
$628M
| $677K | ﹤0.01% |
6,456
+274
| +4% | +$28.8K |
|
1704
Abercrombie & Fitch
ANF
$5.24B
| $677K | ﹤0.01% |
29,551
-54,425
| -65% | -$1.07M |
|
|
NVEE
1705
DELISTED
NV5 Global
NVEE
| $676K | ﹤0.01% |
20,432
-8,236
| -29% | -$286K |
|
|
TPIC
1706
DELISTED
TPI Composites
TPIC
| $674K | ﹤0.01% |
66,492
+43,914
| +194% | +$458K |
|
1707
Coherus Oncology
CHRS
$187M
| $673K | ﹤0.01% |
84,992
+47,670
| +128% | +$367K |
|
1708
Xencor
XNCR
$1.64B
| $672K | ﹤0.01% |
25,804
+15,672
| +155% | +$438K |
|
1709
Cohu
COHU
$2.5B
| $670K | ﹤0.01% |
20,911
-44,226
| -68% | -$1.43M |
|
|
CSR
1710
Centerspace
CSR
$920M
| $670K | ﹤0.01% |
11,419
-1,006
| -8% | -$65K |
|
1711
Inspired Entertainment
INSE
$164M
| $669K | ﹤0.01% |
52,835
-42,717
| -45% | -$474K |
|
1712
Axsome Therapeutics
AXSM
$11.1B
| $669K | ﹤0.01% |
8,677
-3,108
| -26% | -$186K |
|
|
FRG
1713
DELISTED
Franchise Group, Inc.
FRG
| $661K | ﹤0.01% |
27,742
+15,831
| +133% | +$413K |
|
1714
Edgewell Personal Care
EPC
$1.32B
| $658K | ﹤0.01% |
17,074
+2,229
| +15% | +$88.5K |
|
1715
Harmonic Inc
HLIT
$1.24B
| $658K | ﹤0.01% |
50,207
+10,777
| +27% | +$150K |
|
1716
ATI
ATI
$31.3B
| $655K | ﹤0.01% |
21,920
+5,895
| +37% | +$173K |
|
1717
Columbia Banking Systems
COLB
$8.97B
| $654K | ﹤0.01% |
21,713
+174
| +0.8% | +$5.53K |
|
1718
The Joint Corp
JYNT
$121M
| $653K | ﹤0.01% |
46,729
-40,355
| -46% | -$623K |
|
1719
St. Joe Company
JOE
$3.89B
| $649K | ﹤0.01% |
16,795
-1,030
| -6% | -$36.9K |
|
1720
Ameresco
AMRC
$1.37B
| $645K | ﹤0.01% |
11,283
-1,554
| -12% | -$94.7K |
|
1721
Kratos Defense & Security Solutions
KTOS
$12B
| $643K | ﹤0.01% |
62,326
+12,749
| +26% | +$127K |
|
1722
Syndax Pharmaceuticals
SNDX
$1.81B
| $641K | ﹤0.01% |
25,175
+3,246
| +15% | +$75.7K |
|
|
HI
1723
DELISTED
Hillenbrand
HI
| $640K | ﹤0.01% |
14,999
+1,411
| +10% | +$62.5K |
|
|
KALV
1724
DELISTED
KalVista Pharmaceuticals
KALV
| $637K | ﹤0.01% |
+94,284
| New | +$505K |
|
1725
Hyster-Yale Materials Handling
HY
$619M
| $635K | ﹤0.01% |
25,095
-19,102
| -43% | -$532K |
|
Similar funds
VGA
AQR Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, AQR Capital Management held 2,343 positions worth $43.9B, up 7% from $41B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
AQR Capital Management's Q4 2022 filing shows 170 new, 997 increased, 1,015 reduced and 150 closed positions. Its largest new stake was Generac Holdings: 310,080 shares worth $30.5M. The largest sale was Gilead Sciences, an estimated $138M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q4 2022 buy was Generac Holdings: 310,080 shares worth $30.5M.
- AQR Capital Management added most to Humana in Q4 2022, an estimated $111M increase.
- AQR Capital Management's biggest Q4 2022 reduction was Gilead Sciences, cutting an estimated $138M.
- AQR Capital Management fully exited Abiomed Inc in Q4 2022, selling an estimated $22.4M.
- AQR Capital Management's ten largest holdings make up 13% of its $43.9B portfolio in Q4 2022.
- AQR Capital Management opened 170 new positions and closed 150 in Q4 2022.
- AQR Capital Management's portfolio value rose 7% quarter-over-quarter to $43.9B.
Based on AQR Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.